Levitee Labs Appoints Noha ElSayed as Executive Director for Levitee Clinics and Levitee Pharmacies in the Alberta Region
- Levitee adds Noha ElSayed, an expert in compounding and pharmacy operations, to the Levitee Clinics and Levitee Pharmacies management team
- ElSayed has over 20 years of experience as a pharmacist with specialization in
addiction medicine, ketamine compounding, and hepatitis C treatments
- ElSayed is initially responsible for managing the oversight and optimization of five clinics and three specialized pharmacies in Alberta, with additions expected within the franchise
VANCOUVER, BC, CANADA, November 15th, 2021 /CNW/ – Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the “Company” or “Levitee”), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, today announces the appointment of Noha ElSayed, B.Sc.Pharm, APA, as Executive Director, Levitee Clinics and Levitee Pharmacies, Alberta Region. Mrs. ElSayed brings a wealth of expertise gained through a variety of clinical and managerial positions held in retail pharmacies, hospitals, and primary care settings while working as a pharmacist for the last 20 years, including 11 years as a pharmacy manager.
Mrs. ElSayed earned her Bachelor of Science degree in Pharmacy and obtained her Additional Prescribing Authorities from The Alberta College of Pharmacists. She is an active member of several specialized health care networks as the International Society of Travel Medicine and The Canadian Obesity Network. Mrs. ElSayed has a passion for mental health care, addiction treatment, custom compounding, and travel health, as well as diabetes and chronic disease management education. She prides herself on staying up-to-date with the latest pharmacy practices and procedures and is an expert in custom compounding techniques and knowledge.
Mrs. ElSayed is also a specialist and expert in:
- Addiction and Mental Health
- Hepatitis C
- Ketamine compounding
- Pharmacy operations and optimization
- Establishing new (greenfield) pharmacies focusing on operational excellence
- Pharmacy supply chain strategies and optimization
“We’re thrilled to welcome Noha to the Levitee Clinics and Levitee Pharmacies team where her comprehensive pharmacy experience and business acumen will be invaluable to optimizing operations as we continue to execute on our roll-up strategy,” said Pouya Farmand, Chief Executive Officer at Levitee Labs. “She is the perfect fit for our go-forward plans, including production and distribution of pharmaceutical products and our intentions to add treatments for common medical comorbidities associated with addiction and mental health conditions, such as psychiatry, cardiology, and endocrinology.”
“I relish the opportunity to lead the Alberta Region of Levitee Clinics and Levitee Pharmacies, as our visions are aligned for a team-oriented, holistic, patient-centered approach to safely help Albertans across the disease spectrum with the latest technologies,” commented Noha ElSayed. “Levitee Labs is closing gaps in healthcare and I look forward to the future, where specialized and cutting-edge therapies are accessible for all in need.”
Mrs. ElSayed will be responsible for managing Levitee’s Alberta healthcare assets. The Company in October signed a letter of intent to acquire a controlling interest in an addiction and compounding pharmacy in Calgary and continues to explore opportunities to add to its pharmacy franchise that will be within Mrs. ElSayed’s purview.
About Levitee Labs Inc.
Levitee is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies. The Company’s current portfolio of assets includes: Levitee Clinics™, a group of five operating addiction and pain treatment clinics in Alberta; Levitee Pharmacies™, three pharmacies operating in Alberta specialized in filling prescriptions for patients with substance use disorders, mental health conditions, and chronic pain; BlockMD, the first technology company in Alberta to receive provincial approval for electronic-prescriptions in the addiction treatment space; and Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and superfood products with 180+ SKUs in its product lineup across three brands. Further information about Levitee is available on its website at www.leviteelabs.com.
This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements respecting Levitee’s business plans and proposed products, and the benefits derived from mushroom-infused products; the expected use of proceeds from the Loan; the acquisitive growth potential of Levitee once acquisitions are completed; the expectation that Levitee will continue to execute its accretive acquisition program, and the contribution of such program to Levitee’s future growth potential; the closing of Tranche 1, including Levitee’s ability to satisfy the Tranche 1 closing conditions; the closing of any future tranches under the Loan, including Levitee’s ability to satisfy the closing conditions for future tranches of the Loan; and Levitee’s objective to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. These statements and other forward-looking information are based on assumptions made by Levitee based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release as well as management’s current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. These assumptions may also be based on information obtained from third-party industry analysts and other third-party sources. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Levitee as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: Levitee’s limited history of operations; ability to secure additional financing; negative cash flow from operating activities since inception; regulatory requirements; changes in consumer preferences; supply of raw materials; reliance on a limited number of products; brand awareness; the ability to develop, market and produce new products; dependence on certain key senior managers; reliance on third parties for manufacturing and packaging; potential product liability claims and product recalls; and significant competition. For additional information regarding these risks, please see the risk factors identified and reported in Levitee’s public filings under its SEDAR profile at www.sedar.com. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking statements or information. The forward-looking information is made as of the date of this news release, and Levitee assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release and accepts no responsibility for the adequacy or accuracy hereof.
For further information about Levitee Labs Inc., please contact:
Investor and Corporate Communications: